Last reviewed · How we verify

Premature Luteinizing Hormone Surges — Treatment Landscape & Competitive Intelligence

Premature Luteinizing Hormone Surges (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Premature Luteinizing Hormone Surges, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cetrotide CETRORELIX Merck KGaA Gonadotropin Releasing Hormone Receptor Antagonist Gonadotropin-releasing hormone receptor 2000-01-01
Cetrotide Cetrotide Wolfson Medical Center Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck KGaA · 1 drug in Premature Luteinizing Hormone Surges
  2. Wolfson Medical Center · 1 drug in Premature Luteinizing Hormone Surges

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Premature Luteinizing Hormone Surges:

Cite this brief

Drug Landscape (2026). Premature Luteinizing Hormone Surges — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/premature-luteinizing-hormone-surges. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing